These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 26670403)

  • 1. Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia.
    Friedrisch JR; Cançado RD
    Rev Bras Hematol Hemoter; 2015; 37(6):400-5. PubMed ID: 26670403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous iron therapy: how far have we come?
    Cançado RD; Muñoz M
    Rev Bras Hematol Hemoter; 2011; 33(6):461-9. PubMed ID: 23049364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
    Qunibi WY
    Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC; Geisser P
    Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia.
    Montandon SV; Fajt ML; Petrov AA
    Curr Drug Saf; 2016; 11(2):145-8. PubMed ID: 26647917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease.
    Koduru P; Abraham BP
    Therap Adv Gastroenterol; 2016 Jan; 9(1):76-85. PubMed ID: 26770269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ferric carboxymaltose: a review of its use in iron deficiency.
    Keating GM
    Drugs; 2015 Jan; 75(1):101-27. PubMed ID: 25428711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
    Khalafallah AA; Hyppa A; Chuang A; Hanna F; Wilson E; Kwok C; Yan C; Gray Z; Mathew R; Falloon P; Dennis A; Pavlov T; Allen JC
    Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
    Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
    J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.
    Jahn MR; Andreasen HB; Fütterer S; Nawroth T; Schünemann V; Kolb U; Hofmeister W; Muñoz M; Bock K; Meldal M; Langguth P
    Eur J Pharm Biopharm; 2011 Aug; 78(3):480-91. PubMed ID: 21439379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of iv iron compounds over the last century.
    Macdougall IC
    J Ren Care; 2009 Dec; 35 Suppl 2():8-13. PubMed ID: 19891680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
    Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
    Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy.
    Froessler B; Gajic T; Dekker G; Hodyl NA
    Arch Gynecol Obstet; 2018 Jul; 298(1):75-82. PubMed ID: 29740690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of different intravenous iron preparations in terms of total oxidant and total antioxidant status, single center data.
    Can F; Yılmaz KN; Kösemehmetoglu OS; Akıncı S; Güney T
    Ann Hematol; 2023 Oct; 102(10):2645-2650. PubMed ID: 37432415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System.
    Trumbo H; Kaluza K; Numan S; Goodnough LT
    Drug Saf; 2021 Jan; 44(1):107-119. PubMed ID: 33237523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
    Sobrado CW; Cançado RD; Sobrado LF; Frugis MO; Sobrado MF
    Arq Gastroenterol; 2015 Dec; 52(4):255-9. PubMed ID: 26840464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The available intravenous iron formulations: History, efficacy, and toxicology.
    Auerbach M; Macdougall I
    Hemodial Int; 2017 Jun; 21 Suppl 1():S83-S92. PubMed ID: 28371203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA).
    Neiser S; Koskenkorva TS; Schwarz K; Wilhelm M; Burckhardt S
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27455240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the reported rates of hypersensitivity reactions associated with iron dextran and ferric carboxymaltose based on global data from VigiBase™ and IQVIA™ MIDAS® over a ten-year period from 2008 to 2017.
    Durup D; Schaffalitzky de Muckadell P; Strom CC
    Expert Rev Hematol; 2020 May; 13(5):557-564. PubMed ID: 32129113
    [No Abstract]   [Full Text] [Related]  

  • 20. Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice.
    Bhandari S
    Ther Clin Risk Manag; 2011; 7():501-9. PubMed ID: 22241947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.